The University of Chicago Header Logo

Connection

Derek Wainwright to Indoleamine-Pyrrole 2,3,-Dioxygenase

Back to Details
This is a "connection" page, showing publications Derek Wainwright has written about Indoleamine-Pyrrole 2,3,-Dioxygenase.
Derek Wainwright
Connection Strength
6.738
Indoleamine-Pyrrole 2,3,-Dioxygenase
  1. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem. 2022 12 08; 65(23):15642-15662.
    View in: PubMed
    Score: 0.817
  2. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
    View in: PubMed
    Score: 0.691
  3. Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods Enzymol. 2019; 629:235-256.
    View in: PubMed
    Score: 0.649
  4. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2559-2573.
    View in: PubMed
    Score: 0.589
  5. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018 May; 15(5):447-457.
    View in: PubMed
    Score: 0.586
  6. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017 May; 62:24-29.
    View in: PubMed
    Score: 0.547
  7. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015 Dec 15; 21(24):5427-33.
    View in: PubMed
    Score: 0.501
  8. The role of IDO in brain tumor immunotherapy. J Neurooncol. 2015 Jul; 123(3):395-403.
    View in: PubMed
    Score: 0.472
  9. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014 Oct 15; 20(20):5290-301.
    View in: PubMed
    Score: 0.449
  10. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012 Nov 15; 18(22):6110-21.
    View in: PubMed
    Score: 0.402
  11. Tryptophan metabolism in brain tumors - IDO and beyond. Curr Opin Immunol. 2021 06; 70:57-66.
    View in: PubMed
    Score: 0.182
  12. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.
    View in: PubMed
    Score: 0.173
  13. Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). Oncoimmunology. 2019; 8(3):1548242.
    View in: PubMed
    Score: 0.156
  14. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. J Neurooncol. 2019 Jan; 141(1):111-120.
    View in: PubMed
    Score: 0.155
  15. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 01; 23(21):6650-6660.
    View in: PubMed
    Score: 0.141
  16. Advanced age negatively impacts survival in an experimental brain tumor model. Neurosci Lett. 2016 Sep 06; 630:203-208.
    View in: PubMed
    Score: 0.132
  17. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
    View in: PubMed
    Score: 0.050
  18. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.